PPI use raises the risk of T2DM
Screening for diabetes or abnormal glucose levels is recommended for patients whose use of the therapy is long-term
PPI use is associated with a 24% increased risk of developing type 2 diabetes, according to a study drawing on data from three large cohorts.
Researchers analysed prospective data from the all-female US Nurses’ Health cohort (studies I and II), which had a median follow-up of 12 years, and the all-male US Health Professionals Follow-up Study, with a median follow-up of nearly 10 years.
